Common variant of PROK1 (V67i) acts as a genetic modifier in early human pregnancy through down-regulation of gene expression

International Journal of Molecular Sciences

Volumn 17, Issue 2, 2016, Pages

  Su, Mei Tsz ^a   Huang, Jyun Yuan ^a   Tsai, Hui Ling ^a   Chen, Yi Chi ^b   Kuo, Pao Lin ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Calcium influx; Cell invasion; Modifier gene; PROK1 EG VEGF; Prokineticin 1; Recurrent miscarriage

Indexed keywords

PROKINETICIN RECEPTOR 1; PROKINETICIN RECEPTOR 2; RECEPTOR; UNCLASSIFIED DRUG; CALCIUM; ENDOCRINE GLAND DERIVED VASCULAR ENDOTHELIAL GROWTH FACTOR; G PROTEIN COUPLED RECEPTOR; GASTROINTESTINAL HORMONE; PROK1 PROTEIN, HUMAN;

ARTICLE; CALCIUM TRANSPORT; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; MODIFIER GENE; PREGNANCY; PROK1 V67I GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CELL LINE; CELL MOTION; COMPARATIVE STUDY; CYTOLOGY; FEMALE; GENETICS; HEK293 CELL LINE; METABOLISM; SINGLE NUCLEOTIDE POLYMORPHISM; TROPHOBLAST;

CALCIUM; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GASTROINTESTINAL HORMONES; GENES, MODIFIER; HEK293 CELLS; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREGNANCY; RECEPTORS, G-PROTEIN-COUPLED; TROPHOBLASTS; VASCULAR ENDOTHELIAL GROWTH FACTOR, ENDOCRINE-GLAND-DERIVED;

EID: 84957108282     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17020162     Document Type: Article

References (35)

1. Ferrara, N.; LeCouter, J.; Lin, R.; Peale, F. EG-VEGF and Bv8: A novel family of tissue-restricted angiogenic factors. Biochim. Biophys. Acta 2004, 1654, 69–78. [CrossRef] [PubMed]
2. Ferrara, N.; Frantz, G.; LeCouter, J.; Dillard-Telm, L.; Pham, T.; Draksharapu, A.; Giordano, T.; Peale, F. Differential Expression of the Angiogenic Factor Genes Vascular Endothelial Growth Factor (VEGF) and Endocrine Gland-Derived VEGF in Normal and Polycystic Human Ovaries. Am. J. Pathol. 2003, 162, 1881–1893. [CrossRef]
3. Fraser, H.M.; Bell, J.; Wilson, H.; Taylor, P.D.; Morgan, K.; Anderson, R.A.; Duncan W.C. Localization and Quantification of Cyclic Changes in the Expression of Endocrine Gland Vascular Endothelial Growth Factor in the Human Corpus Luteum. J. Clin. Endocrinol. Metab. 2005, 90, 427–434. [CrossRef] [PubMed]
4. Hoffmann, P.; Feige, J.J.; Alfaidy, N. Expression and Oxygen Regulation of Endocrine Gland-Derived Vascular Endothelial Growth Factor/Prokineticin-1 and Its Receptors in Human Placenta during Early Pregnancy. Endocrinology 2006, 147, 1675–1684. [CrossRef] [PubMed]
5. LeCouter, J.; Kowalski, J.; Foster, J.; Hass, P.; Zhang, Z.; Dillard-Telm, L.; Frantz, G.; Rangell, L.; DeGuzman, L.; Keller, G.A et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 2001, 412, 877–884. [CrossRef] [PubMed]
6. Ngan, E.S.; Lee, K.Y.; Yeung, W.S.; Ngan, H.Y.; Ng, E.H.; Ho, P.C. Endocrine Gland-Derived Vascular Endothelial Growth Factor Is Expressed in Human Peri-implantation Endometrium, But Not in Endometrial Carcinoma. Endocrinology 2006, 147, 88–95. [CrossRef] [PubMed]
7. Evans, J.; Catalano, R.D.; Morgan, K.; Critchley, H.O.; Millar, R.P.; Jabbour, H.N. Prokineticin 1 Signaling and Gene Regulation in Early Human Pregnancy. Endocrinology 2008, 149, 2877–2887. [CrossRef] [PubMed]
8. Haouzi, D.; Mahmoud, K.; Fourar, M.; Bendhaou, K.; Dechaud, H.; De Vos, J.; Rème1, T.; Dewailly, D.; Hamamah, S. Identification of new biomarkers of human endometrial receptivity in the natural cycle. Hum. Reprod. 2009, 24, 198–205. [CrossRef] [PubMed]
9. Denison, F.C.; Battersby, S.; King, A.E.; Szuber, M.; Jabbour, H.N. Prokineticin-1: A Novel Mediator of the Inflammatory Response in Third-Trimester Human Placenta. Endocrinology 2008, 149, 3470–3477. [CrossRef] [PubMed]
10. Brouillet, S.; Hoffmann, P.; Feige, J.J.; Alfaidy, N. EG-VEGF: A key endocrine factor in placental development. Trends Endocrinol. Metab. 2012, 23, 501–508. [CrossRef] [PubMed]
11. Gorowiec, M.R.; Catalano, R.D.; Norman, J.E.; Denison, F.C.; Jabbour, H.N. Prokineticin 1 Induces Inflammatory Response in Human Myometrium: A Potential Role in Initiating Term and Preterm Parturition. Am. J. Pathol. 2011, 179, 2709–2719. [CrossRef] [PubMed]
12. Shaw, J.L.; Denison, F.C.; Evans, J.; Durno, K.; Williams, A.R.; Entrican, G.; Critchley, H.O.D.; Jabbour, H.N.; Horne, A.W. Evidence of prokineticin dysregulation in fallopian tube from women with ectopic pregnancy. Fertil. Steril. 2010, 94, 1601–1608. [CrossRef] [PubMed]
13. Hoffmann, P.; Saoudi, Y.; Benharouga, M.; Graham, C.H.; Schaal, J.P.; Mazouni, C.; Feige, J.J.; Alfaidy, N. Role of EG-VEGF in human placentation: Physiological and pathological implications. Cell. Mol. Life Sci. 2009, 13, 2224–2235. [CrossRef] [PubMed]
14. Alfaidy, N.; Hoffmann, P.; Gillois, P.; Gueniffey, A.; Lebayle, C.; Garçin, H.; Thomas-Cadi, C.; Bessonnat, J.; Coutton, C.; Villaret, L. et al. PROK1 level in the follicular microenvironment: A new non-invasive predictive biomarker of embryo implantation. J. Clin. Endocrinol. Metab. 2015. [CrossRef] [PubMed]
15. Alfaidy, N.; Hoffmann, P.; Boufettal, H.; Samouh, N.; Aboussaouira, T.; Benharouga, M.; Feige, J.J.; Brouillet, S. The Multiple Roles of EG-VEGF/PROK1 in Normal and Pathological Placental Angiogenesis. Biomed. Res. Int. 2014, 2014, 451906. [CrossRef] [PubMed]
16. Su, M.T.; Lin, S.H.; Lee, I.W.; Chen, Y.C.; Hsu, C.C.; Pan, H.A.; Kuo, P.L. Polymorphisms of endocrine gland-derived vascular endothelial growth factor gene and its receptor genes are associated with recurrent pregnancy loss. Hum. Reprod. 2010, 25, 2923–2930. [CrossRef] [PubMed]
17. Su, M.T.; Lin, S.H.; Chen, Y.C.; Kuo, P.L. Gene-gene interactions and risk of recurrent miscarriages in carriers of endocrine gland–derived vascular endothelial growth factor and prokineticin receptor polymorphisms. Fertil. Steril. 2014, 102, 1071–1077. [CrossRef] [PubMed]
18. Su, M.T.; Lin, S.H.; Chen, Y.C.; Wu, L.W.; Kuo, P.L. Prokineticin receptor variants (PKR1-I379V and PKR2-V331M) are protective genotypes in human early pregnancy. Reproduction 2013, 146, 63–73. [CrossRef] [PubMed]
19. Andreasen, L.; Nielsen, J.B.; Christophersen, I.E.; Holst, A.G.; Sajadieh, A.; Tveit, A.; Haunsø, S.; Svendsen, J.H.; Schmitt, N.; Olesen, M.S. Genetic Modifier of the QTc Interval Associated With Early-Onset Atrial Fibrillation. Can. J. Cardiol. 2013, 29, 1234–1240.
20. Flanigan, K.M.; Ceco, E.; Lamar, K.M.; Kaminoh, Y.; Dunn, D.M.; Mendell, J.R.; King, W.M.; Pestronk, A.; Florence, J.M.; Mathews, K.D et al. LTBP4 genotype predicts age of ambulatory loss in duchenne muscular dystrophy. Ann. Neurol. 2013, 73, 481–488. [CrossRef] [PubMed]
21. Barry, E.L.; Poole, E.M.; Baron, J.A.; Makar, K.W.; Mott, L.A.; Sandler, R.S.; Ahnen, D.J.; Bresalier, R.S.; McKeown-Eyssen, G.E.; Ulrich, C.M. CYP2C9 Variants Increase Risk of Colorectal Adenoma Recurrence and Modify Associations with Smoking but Not Aspirin Treatment. Cancer Causes Control 2013, 24, 47–54. [CrossRef] [PubMed]
22. Solomon, O.; Bazak, L.; Levanon, E.Y.; Amariglio, N.; Unger, R.; Rechavi, G.; Eyal, E. Characterizing of functional human coding RNA editing from evolutionary, structural, and dynamic perspectives. Proteins 2014, 82, 3117–3131. [CrossRef] [PubMed]
23. Brouillet, S.; Murthi, P.; Hoffmann, P.; Salomon, A.; Sergent, F.; de Mazancourt, P.; Dakouane-Giudicelli, M.; Dieudonné, M.N.; Rozenberg, P.; Vaimanet, D. et al. EG-VEGF controls placental growth and survival in normal and pathological pregnancies: Case of fetal growth restriction (FGR). Cell. Mol. Life Sci. 2013, 70, 511–525. [CrossRef] [PubMed]
24. Kaufmann, P.; Black, S.; Huppertz, B. Endovascular Trophoblast Invasion: Implications for the Pathogenesis of Intrauterine Growth Retardation and Preeclampsia. Biol. Reprod. 2003, 69, 1–7. [CrossRef] [PubMed]
25. Bălu, S.; Pirtea, L.; Gaje, P.; Cîmpean, A.M.; Raica, M. The immunohistochemical expression of endocrine gland-derived-VEGF (EG-VEGF) as a prognostic marker in ovarian cancer. Rom. J. Morphol. Embryol. 2012, 53, 479–483. [PubMed]
26. Goi, T.; Nakazawa, T.; Hirono, Y.; Yamaguchi, A. Prokineticin 1 expression in gastrointestinal tumors. Anticancer Res. 2013, 33, 5311–5315. [PubMed]
27. Ren, L.; Guo, X.; Shao, X.; Li, H.; Yao, H. Endocrine gland-derived vascular endothelial growth factor modulates proliferation, apoptosis and migration in pancreatic cancer cells. Mol. Med. Rep. 2015, 11, 4279–4284. [CrossRef] [PubMed]
28. Torres, C.; Linares, A.; Alejandre, M.J.; Palomino-Morales, R.J.; Caba, O.; Prados, J.; Aránega, A.; Delgado, J.R.; Irigoyen, A.; Martínez-Galánet, J et al. Prognosis Relevance of Serum Cytokines in Pancreatic Cancer. BioMed Res. Int. 2015, 2015, 518284. [CrossRef] [PubMed]
29. Nakazawa, T.; Goi, T.; Hirono, Y.; Yamaguchi, A. Prokineticin 1 protein expression is a useful new prognostic factor for human sporadic colorectal cancer. Ann. Surg. Oncol. 2015, 22, 1496–1503. [CrossRef] [PubMed]
30. Pasquali, D.; Rossi, V.; Staibano, S.; de Rosa, G.; Chieffi, P.; Prezioso, D.; Mirone, V.; Mascolo, M.; Tramontano, D.; Bellastella, A. et al. The endocrine-gland-derived vascular endothelial growth factor (EG-VEGF)/Prokineticin 1 and 2 and receptor expression in human prostate: Up-regulation of EG-VEGF/Prokineticin 1 with malignancy. Endocrinology 2006, 147, 4245–4251. [CrossRef] [PubMed]
31. Swaggart, K.A.; Demonbreun, A.R.; Vo, A.H.; Swanson, K.E.; Kim, E.Y.; Fahrenbach, J.P.; Holley-Cuthrell, J.; Eskin, A.; Chen, Z.; Squire, K. et al. Annexin A6 modifies muscular dystrophy by mediating sarcolemmal repair. Proc. Natl. Acad. Sci. USA 2014, 111, 6004–6009. [CrossRef] [PubMed]
32. Sproule, T.J.; Bubier, J.A.; Grandi, F.C.; Sun, V.Z.; Philip, V.M.; McPhee, C.G.; Adkins, E.B.; Sundberg, J.P.; Roopenian, D.C. Molecular Identification of Collagen 17a1 as a Major Genetic Modifier of Laminin Gamma 2 Mutation-Induced Junctional Epidermolysis Bullosa in Mice. PLoS Genet. 2014, 10, e1004068. [CrossRef] [PubMed]
33. Cooper-Knock, J.; Shaw, P.J.; Kirby, J. The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. Acta Neuropathol. 2014, 127, 333–345. [CrossRef] [PubMed]
34. Van Blitterswijk, M.; Mullen, B.; Heckman, M.G.; Baker, M.C.; DeJesus-Hernandez, M.; Brown, P.H.; Murray, M.E.; Hsiung, G.H.R.; Stewartc, H.; Karydasd, A.M. et al. Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiol. Aging 2014, 35, 2421.e13–2421.e17. [CrossRef] [PubMed]
35. Heydemann, A.; Huber, J.M.; Demonbreun, A.; Hadhazy, M.; McNally, E.M. Genetic background influences muscular dystrophy. Neuromuscul. Disord. 2005, 15, 601–609. [CrossRef] [PubMed]